Intellia Therapeutics (NTLA) Research & Development (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Research & Development of $80.7 million for Q1 2026, down 25.54% year-over-year from $108.4 million in Q1 2025, and down 8.93% quarter-over-quarter from $88.7 million in Q4 2025.
Intellia Therapeutics (NTLA) Research & Development (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Research & Development for 12 consecutive years, with $80.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 25.54% year-over-year to $80.7 million; the TTM figure through Mar 2026 stood at $361.2 million (down 21.97% YoY), while the FY2025 annual figure was $388.9 million, down 16.61% from the prior year.
- Research & Development eased to $80.7 million in Q1 2026 per NTLA's latest filing, from $88.7 million in the prior quarter.
- Across five years, Research & Development topped out at $133.1 million in Q1 2022 and bottomed at $80.7 million in Q1 2026.
- Historically, Research & Development has averaged $105.4 million across 5 years, with a median of $108.4 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development jumped 238.87% — and 2023, when it fell 27.03%.
- Intellia Therapeutics' Research & Development stood at $100.0 million in 2022, then advanced by 8.94% to $109.0 million in 2023, then gained by 7.25% to $116.9 million in 2024, then fell by 24.15% to $88.7 million in 2025, then decreased by 8.93% to $80.7 million in 2026.
- Business Quant data shows NTLA's Research & Development at $80.7 million in Q1 2026, $88.7 million in Q4 2025, and $94.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 82.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.60 Mn |
| Mar 31, 2026 | 80.74 Mn |
| Dec 31, 2025 | 88.65 Mn |
| Sep 30, 2025 | 94.75 Mn |
| Jun 30, 2025 | 97.04 Mn |
| Mar 31, 2025 | 108.43 Mn |
| Dec 31, 2024 | 116.88 Mn |
| Sep 30, 2024 | 123.38 Mn |
| Jun 30, 2024 | 114.21 Mn |
| Mar 31, 2024 | 111.85 Mn |
| Dec 31, 2023 | 108.98 Mn |
| Sep 30, 2023 | 113.70 Mn |
| Jun 30, 2023 | 115.28 Mn |
| Mar 31, 2023 | 97.12 Mn |
| Dec 31, 2022 | 100.03 Mn |
| Sep 30, 2022 | 96.65 Mn |
| Jun 30, 2022 | 90.20 Mn |
| Mar 31, 2022 | 133.10 Mn |
| Dec 31, 2021 | 71.16 Mn |
| Sep 30, 2021 | 60.49 Mn |